Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study

Key Points

• The aim is to assess the incidence of amyloid-related imaging abnormalities (ARIA) and health resource utilization in Alzheimer disease patients receiving monoclonal antibody treatments.
• Analyzed real-world evidence data on patients receiving monoclonal antibodies for Alzheimer disease
• Measured cumulative hazard of ARIA incidents and inpatient visit frequency
• Compared findings to traditional randomized clinical trials to assess credibility
• Monoclonal treatment was associated with a higher cumulative hazard of ARIA incidents
• Patients receiving monoclonal antibodies had fewer inpatient visits
• Findings support the value of real-world evidence in evaluating treatment impacts